Evaluation of Ceftazidime-avibactam and Ceftolozane-tazobactam Prescriptions in a Tertiary Hospital for Children in France: An Observational Study, 2017-2022.
Pauline Labé, Maya Husain, Perrine Parize, Marion Grimaud, Charlotte Roy, Robert Ratiney, Jérémie F Cohen, Hervé Lecuyer, Julie Toubiana
{"title":"Evaluation of Ceftazidime-avibactam and Ceftolozane-tazobactam Prescriptions in a Tertiary Hospital for Children in France: An Observational Study, 2017-2022.","authors":"Pauline Labé, Maya Husain, Perrine Parize, Marion Grimaud, Charlotte Roy, Robert Ratiney, Jérémie F Cohen, Hervé Lecuyer, Julie Toubiana","doi":"10.1097/INF.0000000000004768","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, are emerging in pediatric hospitals. New ß-lactam/ ß-lactamase inhibitor combinations exhibit activity against these pathogens; however, there is limited data regarding their use in pediatric populations.</p><p><strong>Objectives: </strong>The study aimed to describe the characteristics of ceftazidime-avibactam (CAZ/AVI) and ceftolozane-tazobactam (C/T) prescriptions in children and assess their appropriateness.</p><p><strong>Methods: </strong>We retrospectively analyzed all CAZ/AVI or C/T prescriptions in children hospitalized in a French tertiary hospital between 2017 and 2022. All clinical, biological, and pharmacological data were collected prospectively as part of the antibiotic monitoring program set up by our antimicrobial stewardship (AMS) team.</p><p><strong>Results: </strong>In total, 50 CAZ/AVI and 25 C/T prescriptions were recorded, which concerned 21 and 20 patients, respectively. All patients had an underlying chronic condition. Most prescriptions originated from Pediatric Intensive Care Units and the Department of Pediatric Pulmonology and were mainly initiated for respiratory tract infections (n = 41/50, 82% of the CAZ/AVI prescriptions and n = 14/25, 56% of the C/T prescriptions). P. aeruginosa was the primary pathogen in documented infections for both CAZ/AVI and C/T prescriptions (n = 26/48, 54% and n = 16/19, 84%, respectively). Almost all prescriptions of CAZ/AVI and C/T were considered appropriate (n = 47/50, 94% for CAZ/AVI and n = 23/25, 92% for C/T, respectively) by the AMS team. Both CAZ/AVI and C/T treatments were well tolerated and resulted in clinical success in 33 (66%) and 19 (76%) cases, respectively.</p><p><strong>Conclusion: </strong>Our study suggests that CAZ/AVI and C/T are reasonable treatment options for children infected with Gram-negative pathogens resistant to carbapenems.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Infectious Disease Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/INF.0000000000004768","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, are emerging in pediatric hospitals. New ß-lactam/ ß-lactamase inhibitor combinations exhibit activity against these pathogens; however, there is limited data regarding their use in pediatric populations.
Objectives: The study aimed to describe the characteristics of ceftazidime-avibactam (CAZ/AVI) and ceftolozane-tazobactam (C/T) prescriptions in children and assess their appropriateness.
Methods: We retrospectively analyzed all CAZ/AVI or C/T prescriptions in children hospitalized in a French tertiary hospital between 2017 and 2022. All clinical, biological, and pharmacological data were collected prospectively as part of the antibiotic monitoring program set up by our antimicrobial stewardship (AMS) team.
Results: In total, 50 CAZ/AVI and 25 C/T prescriptions were recorded, which concerned 21 and 20 patients, respectively. All patients had an underlying chronic condition. Most prescriptions originated from Pediatric Intensive Care Units and the Department of Pediatric Pulmonology and were mainly initiated for respiratory tract infections (n = 41/50, 82% of the CAZ/AVI prescriptions and n = 14/25, 56% of the C/T prescriptions). P. aeruginosa was the primary pathogen in documented infections for both CAZ/AVI and C/T prescriptions (n = 26/48, 54% and n = 16/19, 84%, respectively). Almost all prescriptions of CAZ/AVI and C/T were considered appropriate (n = 47/50, 94% for CAZ/AVI and n = 23/25, 92% for C/T, respectively) by the AMS team. Both CAZ/AVI and C/T treatments were well tolerated and resulted in clinical success in 33 (66%) and 19 (76%) cases, respectively.
Conclusion: Our study suggests that CAZ/AVI and C/T are reasonable treatment options for children infected with Gram-negative pathogens resistant to carbapenems.
期刊介绍：
The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
